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Abstract
The Crk adaptor proteins (Crk and CrkL) constitute an integral part of a network of essential signal
transduction pathways in humans and other organisms that act as major convergence points in
tyrosine kinase signaling. Crk proteins integrate signals from a wide variety of sources, including
growth factors, extracellular matrix molecules, bacterial pathogens, and apoptotic cells. Mounting
evidence indicates that dysregulation of Crk proteins is associated with human diseases, including
cancer and susceptibility to pathogen infections. Recent structural work has identified new and
unusual insights into the regulation of Crk proteins, providing a rationale for how Crk can sense
diverse signals and produce a myriad of biological responses.
Introduction
Crk has a story book history, first emerging in the late
1980s as a novel retroviral gene product, v-Crk or Gag-
Crk, and later serving as a major impetus for unraveling
how modular protein domains assemble into organized
protein-protein networks during signal transduction. The
study of its mechanism of action has been full of unex-
pected and interesting findings, beginning first with a par-
adox as to how an oncogene product without intrinsic
tyrosine kinase activity strongly and selectively increases
cellular tyrosine phosphorylation levels. v-Crk and its cel-
lular homologs, Crk II, Crk I, and the paralog CrkL, com-
prise the prototype of a novel class of regulatory proteins,
called adaptors, composed of modular Src Homology 2
(SH2) and Src Homology 3 (SH3) domains separated by
flexible linker sequences that act as building blocks to
assemble multiprotein complexes. SH2 domains are
structurally conserved protein domains of ~100 amino
acids contained within the Src oncogene and other signal-
ing proteins that bind tyrosine phosphorylated proteins
in the context of short peptide sequences and localize SH2
domains to tyrosine phosphorylated proteins. SH3
domains are structurally conserved domains of ~60
amino acids that bind a consensus sequence of X1-P2-p3-
x4-P5 where 1 and 4 are aliphatic amino acids, 2 and 5 are
always proline, and together this sequence binds to the
hydrophobic pocket of the SH3 domain. There are over
110 SH2 domains and 300 SH3 domains in the human
genome, making this general signaling strategy widely uti-
lized in metazoan cells to transmit intracellular signals. As
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bridge tyrosine phosphorylated proteins to various intrac-
ellular signaling pathways (Figure 1A). An impressive
body of work over the past two decades has demonstrated
that the signal transduction functions of v-Crk, c-Crk, and
CrkL are attributed to the formation of coordinately regu-
lated protein complexes that bind to the SH2 and the
more N-terminal SH3 domain (SH3N) (Figure 1B). The
Crk SH2 domain binds short tyrosine phosphoryated pro-
teins in the context of pTyr-Asp-x-Pro, and the SH3N
domain binds to proteins with signature proline-rich
sequences in the context of Pro-x-x-Pro-x-Lys/Arg (where
x is any amino acid). To function as an adaptor protein,
both the SH2 and SH3N domains need to be operational
in time and space, acting as molecular adhesives to draw
disparate information together to spatially and tempo-
rally regulate signal transduction pathways.
v-Crk, c-Crk, and CrkL family members
The Crk gene product was identified approximately 20
years ago in the form of a transforming gene (Gag-Crk)
encoded in the genome of a defective avian sarcoma retro-
virus called CT10 (chicken tumor Virus 10) [1,2]. A year
later, Vogt and colleagues characterized an independent
avian retrovirus (called ASV-1) isolated from a spontane-
ous tumor in an adult chicken with an oncogene product
virtually identical to Gag-Crk [3]. The most outstanding
feature of CT10- or ASV-1 transformed chicken embryo
fibroblasts (CEFs) results from a selective increase in tyro-
sine phosphorylation of cellular proteins of pp70 and
pp130, initially suggesting CT10 virus encoded a tyrosine
kinase oncogene [4,5]. However, there were clear differ-
ences in the molecular characteristics of the CT10 virus
compared to viruses that encoded tyrosine kinases,
including the lack of induction of a classic "refractive mor-
phology" in CEFs transformed by Rous sarcoma virus
(RSV). Moreover, Northern blotting against a battery of 19
DNA fragments from previously characterized RNA tumor
viruses, including many of the known tyrosine kinase
oncogenes, did not hybridize with CT10 viral fragments,
suggesting that the oncogene in CT10 was different from
all previously identified tyrosine kinase oncogenes [2].
Subsequently, a cDNA encoding the CT10 transforming
gene was isolated and shown to encode a novel gene prod-
uct containing viral gag sequences fused to sequences sim-
ilar to those previously identified in the N-terminal
regulatory region of the Src family kinases. Because v-Crk
lacked intrinsic tyrosine kinase activity, Mayer and col-
leagues named the new gene with an acronym for its pro-
posed function as a transactivator of a cellular tyrosine
kinase, called Crk or CT10 regulator of a tyrosine kinase.
Following the cloning of v-crk or gag-crk, Reichman, et al.
reported the isolation of the cellular homolog of Crk by
screening a chicken brain library using a portion of the v-
crk probe devoid of the retrovirus-derived gag sequences
[6]. Molecular cloning of chicken cellular crk (c-crk)
revealed a molecule with similar structural organization
to v-Crk, but containing a ~50 amino acid proline-rich
linker and an additional C-terminal SH3 domain (SH3C)
(Figure 1B). Matsuda and colleagues characterized two
species of Crk in mammalian cells, Crk II and Crk I,
derived from alternative splicing from a single gene locus
[7]. Structurally, Crk I is more analogous to v-Crk and,
biologically, significantly more transforming than Crk II
when ectopically expressed in NIH 3T3 cells. The onco-
genic activation of Crk by C-terminal truncation in the ret-
roviral genome is reminiscent of the mode of oncogenic
activation of tyrosine kinases, including the activation of
Src in the RSV genome [8,9]. Indeed, it is now clear that
the differences in transforming activities of Crk II and Crk
I rely, at least in part, on a specific post-translational mod-
ification of Crk that involves phosphorylation on Y222 in
chicken (Y221 in mouse and human) [10]. Both Crk II
and CrkL are negatively regulated by autoinhibitory phos-
phorylation events that ultimately block the ability of Crk
to function as an adaptor protein. This is analogous to the
C-terminal tyrosine phoshorylation of Src family kinases
by C-terminal Src Kinase (CSK) [11,12], which allows Src
to adopt an intramolecular pTyr-SH2 "closed" structure
involving the Src SH2 and a C-terminal phosphorylation
motif [13]. Phosphorylation of Crk on Tyr 221 (or CrkL
on Tyr 207) causes intramolecular binding of the linker
region to the SH2 domain, sequestering the SH2 and
SH3N and preventing them from binding target proteins
[14,15]. Subsequent studies have shown that the negative
regulation of Crk II occurs directly via the activity of the
(A). Coupling of signals through modular SH2 and SH3 domainsFigure 1
(A). Coupling of signals through modular SH2 and 
SH3 domains. Signals are initiated via extracellular factors 
that induce intracellular tyrosine phosphorylation (indicated 
by the light switch) which are subsequently relayed to down-
stream targets through SH3 binding partners (indicated by 
arrowhead). (B). Structure of the Crk family of proteins. The 
domains are boxed: SH2, Src homology 2; SH3, Src homol-
ogy 3; Gag, viral group specific antigen; Y221 or Y207, nega-
tive regulatory phosphorylation site. The structure of Src is 
shown at the top of the figure to indicate its spatial arrange-
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the former originally characterized from the Abelson
murine leukemia virus (A-MuLV) [16]. Abl and Arg
appear to be the predominant tyrosine kinases that nega-
tively regulate Crk II (and CrkL) in cells, as CrkY221 phos-
phorylation is virtually undetectable in Abl/Arg (-/-)
double knockout cells. Current theory holds that v-Crk
and Crk I are more transforming than Crk II, mainly
because their C-termini end prior to the regulatory Y221
site, although there are mutations in the v-crk gene that
also may contribute to oncogenicity [16]. Hence, v-Crk
has no clear mechanism to downregulate signals, essen-
tially being locked as a constitutively active adaptor in sig-
nal transduction.
Crk effector pathways: Molecular multi-tasking and signal 
plasticity
The Crk and CrkL proteins have central roles in an aston-
ishingly vast number of biological processes, ranging
from cell proliferation, cell adhesion and migration,
phagocytic and endocytic pathways for apoptotic cells and
parasitic organisms respectively, apoptosis, and regula-
tion of gene expression [17]. Until the introduction of
siRNA technology and knockouts in genetically amenable
systems, the majority of studies on Crk relied on identifi-
cation of binding proteins to specific domains or by over-
expression of wildtype or dominant negative Crk proteins
in reconstituted systems. Because the SH2 and SH3
domains are modular and retain their binding specificity
and affinity when expressed as isolated fragments [4,18],
GST (glutathione S transferase)-pull-down assays, Far-
Western blotting, and yeast two-hybrid approaches per-
mitted the initial characterization of Crk binding partners
and inference of the participating signal transduction
pathways.
Over the past two decades, over 40 cellular proteins have
been identified that bind to the SH2 and SH3N domains,
and for this reason, it is clearly daunting to assign one spe-
cific cellular function to Crk [17]. Indeed, a PubMed
search combining "Crk" and "signaling" returns over 700
articles, and survey of this literature clearly indicates that
the adaptor function of Crk is used repetitively and often
as a signal transduction strategy in the context of both
physiological and pathophysiological situations (Table 1;
and references [2,5,19-73]). Despite such complexity in
Crk transduction outcomes, some general rules apply
regardless of the specific proteins involved. First, the Crk
SH2 domain (the input pathway) binds phosphotyrosine-
containing proteins in an inducible on-and-off switch
mechanism that involves regulated tyrosine phosphoryla-
tion and dephosphorylation. Second, the interactions
between the Crk SH3N domain (the output pathway)
occur constitutively, and these complexes are generally
regulated without post-translational modifications,
although there are a few exceptions whereby tyrosine
phoshorylation has been shown to impinge on SH3-pro-
line-rich assemblages [74]. Therefore, while assigning
functions to Crk, it is important to keep in mind that
input signals depend on the availability of extracellular
hormones and growth factors, the prior history of the cell,
including whether the cell has been stressed or re-stimu-
lated, the state of proliferation or differentiation of the
cell, and other temporal and spatial epigenetic factors that
reflect the physiological and metabolic status of the cell.
As the input signals reflect changes in the cellular environ-
ment, Crk signals are subject to dynamic and plastic regu-
lation, allowing for rapid and dynamic fluxes through
signal transduction pathways that permit pleiotropic
changes in the signaling capabilities of cells. Despite a
detailed understanding of the types of interactions that
exists between Crk and its substrates, there is still a paucity
of information as to how these signals are integrated in
real time and space.
Another important aspect of Crk signaling that requires
definition is to assess which signaling pathways depend
exclusively on Crk or CrkL versus those signaling path-
ways whereby Crk and CrkL can compensate for each
other. Despite considerable homology between Crk II and
CrkL in their SH2 and SH3 domains, development of
knockout mouse models clearly show these gene products
have distinct, non-overlapping roles, during embryonic
development as both Crk knockout and CrkL knockout
mice die perinatally with different developmental defects.
Moreover, in Crk II (-/-) fibroblasts, CrkL proteins were
not overexpressed in a compensatory manner, and vice
versa of CrkII expression in CrkL (-/-) cells, again suggest-
ing little molecular crosstalk at the level of expression in
embryonic cells [75]. Interestingly, mice homozygous for
a null mutation of CrkL show a phenotype characteristic
of DiGeorge/velocardiofacial syndrome, in which neural
crest derived cells fail to differentiate and migrate leading
to defects in cranial and cardiac development [76-78]. Crk
null mice (which lack both Crk II and Crk I) die perina-
tally due to defects in cardiac and skeletal development
[79]. Imaizuma and colleagues generated another mouse
using an exon trap method that lacks Crk II but still
expresses Crk I. Although Crk I expressing mice show no
obvious developmental abnormalities, it is not known
whether these mice develop age-dependent malignancies,
since they die within a few days after birth by unknown
mechanisms [80].
However, in contrast to the aforementioned observations
showing independent roles for CrkL and Crk II during
development, a number of recent studies suggest that Crk
II and CrkL are co-expressed in somatic cells and can com-
pensate to each in cellular signaling. An example of such
redundancy comes from several independent studies dis-Page 3 of 23
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Cell Communication and Signaling 2009, 7:13 http://www.biosignaling.com/content/7/1/13Table 1: Examples of cellular and extracellular stimuli that result in Crk-mediated signal transduction:




v-Crk p130Cas, pp110, paxillin Cellular transformation Mayer et al (1988)
Matsuda et al (1990)
v-Src p130Cas, paxillin, others Cellular transformation Sakai et al (1994)
Bcr-Abl p130Cas, PI3-kinase Cellular transformation, CML Sattler et al (1996)
Growth factor/Tyrosine kinase
NGF/TrkA TrkA, p130Cas Differentiation, neurite outgrowth Hempstead et al (1994)
Ribon et al (1996)
EGF/Her proteins Cbl, p130Cas, BRK Proliferation, receptor internalization Fukazawa et al (1996)
Ojaniemi et al (1997)
Insulin/IGF-1/IR/IGF-R p130Cas, IRS-1, 4BS Mitogenic Signaling Beitner-Johnson et al (1996), Jin et al 
(2000)
PDGF/PDGFRα PDGF-Rα, p130Cas Mitogenic Signaling Anderson et al (1990), Yokote et al 
(1998)
VEGF/VEGFR p130Cas Motility in endothelial cells, 
Angiogenesis
Salameh et al (2005)
HGF/Met Gab1, PI3-kinase Epithelial morphogenesis Garcia-Guzman et al (1999)
Ephrin/EphB2 p130Cas, Cbl Membrane ruffling, tumor growth Noren et al (2006)
Cytokines/Receptors
IL-8/IL-8R p130Cas Cytoskeletal changes Schraw et al (1995)
IL-3/IL-3R; Epo-EpoR Cbl Proliferation Barber at al (1997)
Ang-2/Tie2 p130Cas Vascular smooth muscle cell migration Takahashi et al (1998)
Calcitonin-Calcitonin-R p105CasL Cytoskeletal changes Zhang et al (1999)
IL-2/IL2R STAT-5 Nuclear translocation/Transcription Oda et al (2000)
TGF-β/TGF-β1R p130Cas E-Cadherin cell to cell contact Kim et al (2002)
SLDF-1 p130Cas./JAK2 Cellular migration Zhang et al (2001)
Reelin/ApoER2 Dab1 Neuronal positioning Chen et al (2004)
Crosslinking TCR activation p130Cas, Cbl, ZAP70 Proliferation/Clonal expansion Sawasdiksol et al (1995), Buday et al 
(1996)
LFA/BCR activation p130Cas, Cbl B cell activation/differentiation Petruzzelli et al (1996)
LPA/Bombesin/RhoA p130Cas, paxillin Stress fiber formation/focal adhesions Flinn et al (1996)
GABA/m3 muscarinic-R FAK, p130Cas Exocytosis (pancreatic cells) Rasado et al (2000)
CCL20/CCR6 p130Cas Epithelial cell adhesion/migration Yang et al (2005)Page 4 of 23
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Mechanical force
FN/Integrin β1 p130Cas/FAK Cell adhesion and migration Nojima et al (1996) Armulik et al 
(2000)
uPA/uPAR p130Cas Motility in tumor cells Smith et al (2008)
MCSP/α4β1 integrin p130Cas Tumor invasion Eisenmann et al (1999)
Shear/Mechanical tension p130Cas Src activation/Focal adhesion 
remodeling
Okuda et al (1999), Sawada et al (2006)
Col/Col-R Paxillin Cell Dispersion Petit et al (2000)
Osmotic Stress/Shock Gab1, p130Cas Stress responses Gaul et al (2002)
ECM proteins/Integrins p130Cas Rac1-mediated motility Cho et al (2000)
Laminin 10/11 p130Cas Cellular migration Gu et al (2001)
TIMP-2 Paxillin HVEC motility and invasion Oh et al (2006)
Chondroitin-Sul/Neuropilin p130Cas Axon guidance Liu et al (2007)
HLA ERM proteins Cell migration Tsuda et al (2004)
Particles
Apoptotic cells p130Cas Phagocytosis Reddien et al (2000), Albert et al (2000)
Molecular patterns/CD36 p130Cas Phagocytosis Stuart et al (2007)
Adenovirus/αvβ5 integrin p130Cas Virus endocytosis/trafficking Li et al (2000)
Yersinia p130Cas Pathogen uptake Weidow et al (2000)
Shigella p130Cas/Abl Bacterial uptake Burton et al (2003)
Listeria/InIB receptor Gab1 Bacterial Entry Sun et al (2005)
Helicobactor CagA Entry into Gastric cells Suzuki et al (2005)
Other
Fluoroaluminate p130Cas Spreading of pre-osteoblstic cells Freitas et al (2002)
Shingosine-1-phosphate p130Cas Gi-mediated motility Ohmori et al (2001), Endo et al (2002)
MFG-E8 p130Cas Phagocytosis Akakura et al (2004), Hamayama et al 
(2002)
Estrogen/Tamoxafin Gab1, p130Cas Non-genomic actions of E2 Cabodi et al (2004), Cowell et al (2006)
The data are arranged in potential classes of initiating signals, as well as major tyrosine phosphorylated scaffolds that assemble with Crk or CrkL. For specific examples, 
please see references [2,5,19-73] in the bibliography.
Table 1: Examples of cellular and extracellular stimuli that result in Crk-mediated signal transduction: (Continued)Page 5 of 23
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cells of the hippocampus. Reelin, a secreted glycoprotein
that binds to receptors on hippocampal neurons such as
ApoER2, VLDLR, and α3β1 integrin, controls cell posi-
tioning during adult neurogenesis via Src-dependent tyro-
sine phosphorylation of the scaffold protein Dab1 [81].
Upon receptor activation, Dab1 becomes tyrosine phos-
phorylated at multiple sites, and binds a variety of SH2
domain-containing proteins that include both Crk II and
CrkL [82,83]. Studies using shRNA or cre-lox deletion of
Crk and CrkL showed that knockdown of both proteins
are required for the defects in neuronal positioning, and
both proteins appear to converge on the activation of
Rap1 through C3G (see below) [84-86]. How universal
Crk and CrkL compensation is in signal transmission still
remains an active area of investigation.
Role of p130Cas and molecular scaffolds in signal 
integration and Crk function
Much of the early emphasis on Crk biology focused on the
mechanisms of increased cellular tyrosine phosphoryla-
tion and models for v-Crk transformation. Although it is
still reasonable to consider that v-Crk binds to and
"hijacks" a cellular tyrosine kinase, no model in which a
specific tyrosine kinase is activated has provided a unify-
ing molecular mechanism for v-Crk and Crk I transforma-
tion. However, a number of studies indicate that
expression of v-Crk in Src (-/-) or Fyn (-/-) fibroblasts sig-
nificantly reduces Crk-inducible tyrosine phosphoryla-
tion [87], and such studies imply that v-Crk
transformation, at least in part, requires initial activation
of a Src family kinase member (SFK). Subsequently, Akagi
and colleagues demonstrated that focal adhesion kinase
(FAK) Y397 phosphorylation (mediated by SFKs), and the
recruitment of phosphatidylinositol 3'-OH kinase (PI3K)
to FAK was also required for v-Crk-dependent transforma-
tion of CEFs [88,89]. This observation is consistent with
recent studies employing Src/Fyn/Yes (SFY)-deficient
MEFs, whereby Src was shown to be required for FAK tyro-
sine phosphorylation and Crk-mediated motility [90].
With respect to the substrates of tyrosine phosphorylation
and Crk transformation, a great deal of attention has been
placed on the p130Cas/HEF1/Efs proteins, a family of
non-enzymatic docking proteins that contain multiple
interacting domains and serve as important anchoring
points for protein-protein interactions [46,91]. p130Cas
(Crk associated substrate), the most ubiquitously
expressed member, was in fact discovered as a result of its
elevated phosphotyrosine levels observed in CT10-tran-
formed cells [5,19,92]. The importance of p130Cas in Crk
and Src transformation has been illustrated not only
because p130Cas stably and persistently binds SFKs, but
also from studies that tyrosine kinase and Ras oncogenes
fail to transform p130Cas (-/-) fibroblasts [93,94]. Recent
studies also indicate that p130cas is necessary and suffi-
cient to transform cells, as a transgenic MMTV-p130Cas
mouse that overexpresses p130Cas in the mammary gland
shows extensive mammary epithelial hyperplasia during
development and pregnancy with an association of ele-
vated Src activity [95]. Moreover, a double transgenic line
expressing MMTV-p130Cas and MMTV-HER2-neu devel-
oped multifocal mammary tumors at an accelerated level
[95]. Overexpression of p130Cas also renders breast can-
cer cells more resistant to cytotoxic chemotherapies, such
as anti-estrogen agents or adriamycin, indicating that
p130Cas activates survival and metastatic pathways when
tyrosine phosphorylated [96,97]. Indeed, these studies are
consistent with the fact that highly metastatic breast can-
cer epithelial cells up-regulate β1 integrin and p130Cas,
and show stress fiber formation that correlates with EMT
and motility from the site of tumor origin [98]. Although
to our knowledge v-Crk transformation has not been
reported in p130Cas (-/-) cells, expression of a p130Cas
substrate trap (which essentially contains just the Crk sub-
strate region) effectively abrogates v-Crk transformation
[99]. Since many tumor cells express high amounts of
tyrosine phosphorylated p130Cas, these and other studies
implicate p130cas as a central component for Crk trans-
formation.
Mice with homozygous null mutations of p130Cas
exhibit marked growth retardation with poorly developed
heart and vasculature and die in utero from congestive
heart failure, edema, and hemorrhaging due to break-
down in the regulation of vascular permeability [94]. Iso-
lated and immortalized p130Cas (-/-) embryonic
fibroblasts display short disorganized actin filaments,
show defects in actin bundling, and these cells have small
and poorly organized focal adhesions. However, a func-
tional role for p130Cas in non-motile cell types, including
neurons, is likely equally important and recent studies in
Drosophila showed that targeted loss of p130Cas in CNS
neurons induced defects in neurite guidance and target
fasciculation [100]. In fibroblasts, v-Crk localizes prima-
rily at focal adhesions, and for this reason, the association
of Crk with events associated with p130Cas and actin
cytoskeleton assemblages has gained considerable accept-
ance in the Crk transformation field [101,102]. Specific
targeting of Crk to focal adhesions by fusing a FAT
sequence to Crk induces p130Cas and FAK phosphoryla-
tion and potentiates cell migration [102].
At the molecular level, p130Cas has multiple protein-pro-
tein interaction domains including an N-terminal SH3
domain that binds FAK and Pyk2, an interior "substrate
domain" characterized by 15 YxxP motifs, a C-terminal
Src binding domain, followed by a highly conserved C-
terminal region that binds to the Nsp family of proteins
(Nsp1, And-34, and Chat) [91] (Figure 2A). Based on thePage 6 of 23
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been continued interest and conjecture as to the reasons
why this motif has been duplicated 15 times, since when
phosphorylated, they comprise a consensus binding site
for the SH2 domain of Crk. Interesting studies by Miller
and colleagues showed that the p130Cas substrate region
was processively phosphorylated when Src bound to the
polyproline-region of p130Cas, initially suggesting that
the order of addition of phosphates may organize a pat-
tern to prioritize a signaling mechanism [103]. However,
their more recent studies suggests that p130Cas phospho-
rylation is stochastic, meaning that no single "lynchpin"
permits phosphorylation at additional sites and that the
phosphorylation does not appear to follow an obligatory
sequence [104]. This would suggest that the juxtaposed
repetitiveness of the YxxP motifs in p130Cas would
mainly function in signal amplification to maximize the
Crk output pathways, but also to diversify signaling, as
functional cooperation in the Crk assemblages would also
increase the repertoire of output signals, for example dur-
ing integrin-mediated spreading and migration on extra-
cellular matrix (ECM) molecules [105] (Figure 2C).
Assuming that several of the tyrosines in the YxxP motifs
are concomitantly phosphorylated at any given time, this
might indicate that separate molecular complexes of
p130Cas/Crk/DOCK180, p130Cas/Crk/C3G, p130Cas/
Crk/Abl, p130Cas/Crk/JNK, and p130Cas/Crk/PI3K
could exist simultaneously, but this remains to be seen
experimentally (Figure 2C). Clearly, the development of
site-specific, phospho-specific antibodies aimed to quan-
tify and map the timing and sequence of p130Cas phos-
phorylation events could be used to determine whether
there are more subtle patterns in the motifs that are phos-
phorylated, or perhaps more importantly, whether the
half lives of individual phosphorylation events vary dur-
ing signal downregulation. Such multiplicity in p130Cas
phosphorylation could achieve extraordinary diversifica-
tion in signaling by acting as a molecular scaffold to trans-
mit localized subcellular signals.
The biological role of p130Cas phosphorylation is also
intriguing from the vantage point that a vast variety of
extracellular matrix molecules, growth factors, hormones,
and metabolic intermediates that induce tyrosine phos-
phorylation of p130Cas and subsequent coupling to Crk
(Table 1). In addition, recent studies have demonstrated
that p130Cas phosphorylation is sensitive to physical
transduction by mechanical force [51] and this may pro-
vide a common element for convergence in signal trans-
duction (Figure 2B). These most interesting studies
showed that when cells are cultured on a stretchable sub-
strate consisting of collagen-coated flexible silicone to
uniformly and biaxially stretch cells by 10% or more,
p130Cas was inducibly tyrosine phosphorylated within 1
minute of the stretch. Although these experiments were
designed to mimic integrin-mediated events, it is impor-
tant to note that tyrosine phosphorylation of p130Cas
occurred in the absence of specific integrin ligation and
outside to inside integrin signaling. Moreover, using a
clever FRET-based assay to monitor stretching of the
p130Cas substrate domain (SD) in vitro, these investiga-
tors showed extension-dependent phosphorylation of the
SD by both Src and Abl tyrosine kinases, but not CSK or
ZAP-70. These data suggest that mechanical stretching of
the substrate region, presumably by actin-tethering pro-
teins brought together by binding to FAK and/or Src, is
sufficient to cause p130Cas phopshorylation and subse-
quent coupling to downstream pathways (Figure 2C).
This data also suggests that physiological events that
induce stretching, i.e. adhesion, motility and engulfment
of large particles, as well as pathophysiological events
such as hypertrophy, are probably sufficient to induce
p130Cas tyrosine phosphorylation, independent of the
particularities that initiate the signal.
Structural characteristics and interacting proteins of p130casFigure 2
Structural characteristics and interacting proteins of 
p130cas. (A). p130Cas is a nonezymatic scaffolding protein 
that contains, (i) an N-terminal SH3 domain that binds FAK 
and Pyk2, 15 repeats of a YxxP motif, a serine-rich motif that 
binds Src kinases, and a conserved C-terminal region that 
binds members of the Chat family of proteins. (B). Signal 
transduction by the p130Cas scaffold protein. The central 
substrate region of p130Cas (shown in panel B as a com-
pressed configuration) is activated by mechanical force and 
"extension" of the central region (C). This would activate 
Src, induce tyrosine phosphorylation of the repetitive YxxP 
motifs, and recruit Crk through its SH2 domain. Further, by 
recruiting different proteins via the CrkSH3N, this signaling 
strategy would spatially integrate divergent signals, for exam-
ple, after the recruitment of various GTPase pathways such 
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strate for activated tyrosine kinases, and p130Cas itself
has binding sites for FAK [106] and Pyk2 [107] (via the
SH3 domain) and SFK members through the C-terminal
Src binding region (SBR) [21] (Figure 2A). In vivo, both of
these kinases have been proposed to contribute to
p130Cas phosphorylation, possibly to permit different
mechanisms and different input signals to converge on
assembling Crk linkages [108]. To gain a better perspec-
tive on the specific role of Src versus FAK in mediating
p130Cas phosphorylation, and determine whether phos-
phorylation is sufficient to activate downstream signaling,
Sharma and Mayer [109] developed an approach called
functional interaction trapping (FIT). Using this strategy,
two signaling molecules are brought together by engineer-
ing fusion proteins with artificial binding surfaces com-
posed of two leucine zipper coiled-coiled domains of
ZipA and ZipB. When FIT was employed to bring together
full-length p130Cas or the substrate region of p130Cas
and Src, p130Cas was heavily phosphorylated on tyrosine
and phosphorylated 130cas was sufficient to activate Rac1
and localize to focal adhesions [109]. In apparent con-
trast, when FAK was fused with ZipB and expressed with
p130Cas, p130Cas was weakly phosphorylated. This
result appears to resolve a long-standing question as to
whether FAK acts principally as a scaffold, since the
Tyr397 site in FAK can recruit Src family kinase through its
SH2 domain. However, functional studies show that FAK
binding is important for p130Cas tyrosine phosphoryla-
tion in vivo, as fibroblasts derived from mice expressing a
truncated p130Cas that lacks exon 2, and hence the N-ter-
minal SH3 domain that binds FAK, fail to induce p130Cas
phosphorylation when fibroblasts were induced to spread
on FN [110].
Analogous to the theme described above for p130Cas,
other scaffolding molecules that are acted upon by extrin-
sic signals ultimately interact with Crk, thereby launching
alternative versions of a common signaling paradigm.
Numerous stimuli, ranging from growth factors and
cytokines to ECM, apoptotic cells, microbial products,
immune complexes, and endogenous metabolic products
activate trans-membrane receptors that inducibly phos-
phorylate proteins that, in turn, engage the Crk SH2
domain (Table 1). These proteins include Dab1 [39], IRS-
1 [25], Paxillin [111], Gab1 [112], and CasL/Efs [91], and
analogous to p130Cas, these proteins contain tandem
YxxP motifs. As pointed out by Feller, et al., examination
of the databases shows that the occurrence of three or
more YxxP motifs in 100 kDa intracellular proteins is rare
[17], raising the question of how such tandem elements
are designed for functional crosstalk between Crk adaptor,
or other adaptor protein pathways. As alluded to above,
utilization of different scaffolds could allow for localized
signaling, by virtue of being targeted by specific kinases, or
could control the selectivity of Crk signaling. A good illus-
tration of this comes from a study by Lamorte and col-
leagues, showing that a switch from a p130Cas/Crk to a
Gab1/Crk complex in Met oncogene transformed cells
correlates with a change from a motile phenotype to a
proliferation phenotype [113]. In a few cases, Crk can
interact directly with tyrosine kinase receptors. For exam-
ple, direct recruitment of Crk to the PDGFRα [28] or the
VEGFR-3 [29] can regulate immediate post-receptor sig-
nals from a subset of growth factors at the plasma mem-
brane.
Once the Crk proteins are engaged by tyrosine phopshor-
ylation via the SH2 domain in a particular time and place,
they can transmit signals downstream through constitu-
tive binding to the Crk SH3 domain. Although many Crk
SH3N binding proteins have been identified and have
been the subject of an excellent review [17], some of the
better characterized p130Cas signaling pathways are
described below.
Crk and C3G
C3G (Crk SH3-domain-binding guanine-nucleotide
releasing factor) was isolated in a screen for Crk SH3N-
binding partners and was the first protein identified that
bound to the SH3 domain of Crk [114,115]. In addition
to several proline-rich sequences that bind Crk, C3G has a
guanine nucleotide releasing activity that removes GDP
from the small GTPases Rap1 (Krev-1), Rap-2, and R-Ras,
allowing their spontaneous reloading with GTP [116].
Rap-GTPases (like other Ras-GTPases) are thought to be
inactive when bound to guanosine diphosphate (GDP),
and activated when bound to guanosine triphosphate
(GTP). As their name implies, GTPases possess intrinsic
enzymatic activity that hydrolyses GTP to GDP and phos-
phate. Thus, upon binding to GTP, the duration of Rap-
GTPase activity depends on the rate of hydrolysis. C3G
(and other guanine nucleotide exchange factors) act by
binding Rap-GTPases and catalyzing the release of their
bound GDP nucleotide. Once released from C3G, the Ras-
GTPase quickly binds fresh guanine nucleotide from the
cytosol because cytosolic GTP is approximately ten times
more abundant than cytosolic GDP.
Although Rap1 have strong homology to classic Ras pro-
teins and were initially identified as native antagonists to
Ras that bound to and inhibited Raf-1, Rap1 signaling is
clearly complex and multifactorial, and targets of Rap-1
have been implicated in cell proliferation, cytoskeletal
reorganization during cell adhesion to ECM, and for cell-
to-cell contact [116]. Although expression of "activated"
Rap1V12 in fibroblasts does not induce classic cell trans-
formation analogous to RasV12, Rap1 has been impli-
cated in increased cell proliferation and transformation in
EGF-stimulated Swiss 3T3 fibroblasts that express B-Raf,Page 8 of 23
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In addition, studies in both mice and humans have dem-
onstrated an important role for the RapGAP, Spa-1, in
cancer development. For example, Spa (-/-) targeted mice
show constitutive activation of endogenous Rap1 in
hematopioetic progenitor cells, and these mice exhibit a
marked increase in granulocytic cells analogous to CML,
with a subset showing blast crisis analogous to CML
[119]. Spa-1 polymorphisms that alter Spa-1 activity have
also been correlated with a likelihood for metastastic dis-
ease in humans [120]. In addition to Spa-1 deficiency,
forced expression of C3G has been implicated in T-cell
acute lymphoblastic leukemia [121]. C3G also has been
implicated in the activation of R-Ras, which can activate
the stress-related kinase JNK1 [122,123]. Although the
catalytic activity of C3G is involved in transformation in
rodent fibroblasts, interestingly, sequences outside the
catalytic domain of C3G also have tumor suppressor
activity, and recently PP2A was shown to bind to the N-
terminal region of C3G [124,125]. Finally, in chronic
myelogenous leukemia (CML), a novel truncated form of
C3G (p87), without the inhibitory region, was found to
be associated with Bcr-Abl [126].
One of the most important biological effects of Rap1 sig-
naling is the acute regulation of cell adhesion, in part,
mediated by the activation of integrins. Recruitment of
C3G to the plasma membrane links p130cas to C3G,
where Rap1-GTP increases the affinity of β1 integrins to
ECM, the so-called inside to outside integrin signaling
[127,128]. Rap1 signaling also induces cell spreading and
F-actin dynamics by binding to the Rap1-interacting adap-
tor molecule (RIAM) [129], which may also control E-cad-
herin and cell to cell interactions [130]. Functionally, C3G
activity is potentiated by tyrosine phosphorylation at
Tyr504 [131], mediated by SFKs, and therefore it is likely
that C3G activity coincides with its recruitment to
p130Cas and the activation of Src that accompany cell
adhesion to ECM, following stimulation of cells with cer-
tain cytokines, as well as following stretch-inducible
mechanical force. Tyrosine phosphorylation of C3G is fur-
ther accompanied by its relocation from the cytosol to the
cortical actin cytoskeleton and the trans-Golgi, addition-
ally suggesting a role in protein trafficking or secretion
[132]. In neuronal cells, one of the best-understood func-
tions of p130Cas/Crk/C3G-induced activation of Rap1
involves the activation of B-Raf in neurons. B-Raf forms a
stable complex with Rap1 and converges on a signaling
pathway to sustainably activate the mitogen-activated
protein kinase (MAPK) pathway to control neuroblast dif-
ferentiation [133].
Crk and Son of Sevenless (SOS)
SOS was first identified in Drosophila melanogaster as a
functional gene product downstream of sevenless in the
Ras/MAP kinase pathway [134]. When sevenless is mutated
during development of the fly's ultraviolet light-sensitive
compound eye, the seventh, central photoreceptor (R7) of
each ommatidium fails to form. Subsequent studies indi-
cated that SOS was homologous to the yeast exchange fac-
tor for Ras, CDC25, and then identified as a central
conduit to link receptor tyrosine kinases to Ras following
growth factor stimulation in metazoan cells [135]. In
mammalian cells, there are two SOS homologs, SOS1
(~170 kDa) and SOS2 (~150 kDa) derived from different
genetic loci. The N-terminal of SOS1 encodes a Dbl-
homology (Dbl) and Pleckstrin homology (PH) duet that
exchanges GTP for GDP on Ras, as well as tandem C-ter-
minal proline-rich motifs that interact with several adap-
tor proteins, including Grb2 and E3b1. Although SOS can
interact with both Grb2 and E3b1 (a Rac1 GEF) adaptors
simultaneously, very recent studies indicate that the tim-
ing of these reactions significantly differ in vivo, the Ras
activation occurring in a rapid and transient fashion,
while Rac1 activation occurring in a more sustained and
protracted manner [136].
Both SOS1 and SOS2 possess repetitive proline motifs
that conform to consensus Crk SH3 binding motifs and
direct stable association between Crk and SOS. A func-
tional significance for this interaction is evident from co-
expression studies showing that dominant negative Ras
protein suppresses v-Crk-induced cell transformation in
CEFs [16]. Moreover, in Crk-I transformed NIH3T3 cells,
RNAi downmodulation of SOS1 significantly decreased
cell transformation (soft colony formation) and tumori-
genicity when Crk-I transformed cells were xenografted in
nude mice (Bruce Mayer, personal communication).
Finally, it is also interesting to point out that the major
deficiencies observed in Crk null mice (namely cardiovas-
cular and cranial defects) are also observed in subsets of
patients with Noonan Syndrome. Noonan syndrome is a
congenital syndrome characteristic of multiple abnormal-
ities that include facial dysmorphology and cleft palate,
short stature, and hypertrophic cardiomyopathic defects
that include defects in the vascular smooth muscle archi-
tecture [137]. In about 15–20% of the clinical cases of
Noonan syndrome, SOS1 mutations are present through-
out the coding region of the gene that directly influence
the GEF activity [138]. Future studies aimed at crossing
SOS1 mutant with Crk (-/-) and Crk transgenic mice may
shed additional light on how Crk and SOS interact with
respect to tissue-specific functions.
Crk and DOCK180 (DOCK1)
DOCK180 (Downstream of Crk; DOCK1) was originally
cloned by far-Western blotting, with Crk SH3N domain as
a "bait" molecule [139,140], and represents the third GEF
that directly associates with the Crk SH3 domain. How-
ever, unlike SOS and C3G exchange factors, DOCK1 doesPage 9 of 23
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mote nucleotide exchange. Instead, DOCK1 mediates
nucleotide exchange via a novel evolutionarily conserved
Docker/DHR2/CZH2 domain that recruits ELMO, which
functions in trans as a bipartite Rac-1-GEF [141,142].
Although a complete understanding of the structural
mechanisms for Rac1 activation are still emerging, bio-
chemical studies indicate that DOCK1 must interact with
ELMO for efficient Rac1 activation. The prototypical
member of the ELMO family is ELMO1 that is character-
ized by N-terminal Armidillo repeats, and a PH domain
and proline-rich sequences towards the C-terminus.
The bi-molecular nature of the DOCK1/ELMO Rac-GEF
argues that, in contrast to conventional Rac-GEFs in which
the DH and PH domains act as cis-acting elements, a sig-
nificant aspect of the regulation of DOCK/ELMO medi-
ated catalysis depends on the regulation of the association
between DOCK1 and ELMO proteins, as well as other
trans-acting factors (Figure 3B). In this respect, there are at
least three known mechanisms by which DOCK1 and
ELMO interact, one involving a PxxP-dependent SH3
domain interaction between the C-terminus of ELMO and
the SH3 domain of DOCK1, the second involves atypical
elements within the C-terminus of ELMO that interact
with non-proline rich motifs in the N-terminus of
DOCK1, and third, the ELMO PH domain interacts with
nucleotide-free Rac1. Recent evidence suggests that several
(if not all DOCK family proteins) have the capacity for
structural inhibition mediated by an atypical SH3 domain
interaction between the N-terminal SH3 domain and the
DHR2 region [142]. Binding of ELMO to the SH3 domain
of DOCK1 would not only relieve the inhibition of DHR2
and permit Rac1 to bind to this region, but may also per-
mit PH mediated catalysis. Therefore, one of the impor-
tant strategies to identify the relevance of DOCK180 and
ELMO is to recognize the relevant upstream and down-
stream effectors. A clue into such a pathway was shown in
recent studies that tyrosine phosphorylation of ELMO (by
Src family kinase) is required for Rac-GEF function. In
addition, recent studies indicate that a newly character-
ized phosphatidylserine receptor called BAI can directly
interact with DOCK1 [143], and the RhoG GEF Trio can
directly interact with ELMO [144]. Finally, binding of
ELMO to DOCK1 inhibits the ubiquitylation and degra-
dation of DOCK1 [145], suggesting that DOCK proteins
may also be regulated by protein stability.
Despite the fact that DOCK1 was identified by virtue of its
direct interaction with Crk, it is still not entirely clear
whether Crk binding to DOCK1 directly mediates Rac1
activation at the biochemical level [60,146]. In this
respect, Crk appears to have a secondary function to regu-
late Rac1 activation [147] mediated by the SH3C domain
[148]. Mutations in the SH3C domain of Crk prevent the
regulated turnover of the DOCK1/ELMO complex, sug-
gesting that Crk also controls assembly of the ELMO/
DOCK1 complex. Despite these findings, more recent
functional studies employing LR73 fibroblasts showed
that a direct interaction of Crk II with DOCK1 was dispen-
sable for both engulfment of apoptotic cells as well as for
the recruitment of DOCK1 since expression of mutant
DOCK1 proteins that lack the proline-rich sequences were
sufficient for supporting Rac1 activation [147]. This result
is interesting in that it contrasts earlier genetic studies
identifying Crk II (ced-2) in a linear pathway with DOCK1
(ced-5) (see below) for motility and for engulfing apop-
totic corpses. Moreover, several studies have shown that
dominant negative Crk proteins block migration towards
certain ligands. For example, A549 lung adenocarcinoma
cells and ECV304 endothelial-derived cells adhering to
laminin-10/11 show more robust Rac1 activation com-
pared to these same cells on vitronectin, and further dom-
inant negative Crk proteins that don't interact with
DOCK1 block Rac1 activation [55]. Taken together, these
data imply that there may be Crk/DOCK dependent and
Crk/DOCK independent interactions that depend on the
initiating ligands and upstream tyrosine kinases that
become activated.
(A). Schematic structures of DOCK proteinsFigure 3
(A). Schematic structures of DOCK proteins. The SH3 
domain, Docker Homology Region 1/CDM-Zizimin 
Homology1, Docker Homology Region 2/CDM Zizimin 
Homology 2, and Proline-rich sequences (shown in red) are 
indicated. The circular structure indicates the putative loca-
tion of the Crk binding sites. Note that in DOCK5, Crk has 
been shown to bind to a non-canonical proline sequence. In 
DOCK2, Crk has been proposed to bind independent of 
proline. (B). Structure of the autoinhibited DOCK1/Crk 
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DOCK180/DOCK1 is the prototype of a superfamily of at
least 11 homologous members divided into 4 subfamilies
based on conservation in the DHR1/CZH1 and DHR2/
CZH2 domains as well as their specificity towards Rac1 or
Cdc42 [149,150]. This larger family, called CZH [CDM
(CED/DOCK/Myoblast City)-Zizimin homology] can be
further divided into either DOCK related (specific for
Rac1) or Zizimin related (specific for Cdc42) [151] (Fig-
ure 3A). In terms of relevance to Crk and CrkL, to date
none of the zizimin proteins possess classic PxxPxK, R
motifs that bind Crk SH3 domains, and of the DOCK fam-
ilies, DOCKA (which consists of DOCK1, DOCK2, and
DOCK5), and DOCKB (which consists of DOCK4 and
DOCK3/MOCA), only DOCK1 has conventional Crk SH3
binding sites. However, very recent studies indicate that
DOCK5 participates in Caco-2 cell motility by binding
Crk L and Crk II SH3 domains via atypical proline-rich
motifs in their carboxyl-termini [152]. Similar interac-
tions between DOCK and Crk proteins outside of the clas-
sical PxxPxK motifs have been reported for DOCK2,
which lacks the classic C-terminal region for binding Crk,
and appears to bind CrkL via regions of the DOCKER
domain [153]. Recent studies also suggest that DOCK5
cooperates with DOCK1 for the differentiation of myofib-
ers [154], and clearly, crossing these mice with Crk II (-/-)
or CrkL (-/-) mice should better define the level of func-
tional interactions. If this is generally true, then the role of
Crk signaling in regulating DOCK-C and DOCK-D family
members should be revisited.
Crk and JNK
In addition to the ability of Crk to activate JNK through
C3G and R-Ras noted above, Crk II can also interact with
JNK directly through a proline-rich sequence in JNK and
the SH3N domain of Crk [155]. Similar to the case for
C3G and DOCK180, recruitment of a Crk/JNK complex to
p130Cas may result in the localization to JNK to its rele-
vant upstream kinases, such as MKK4 and HPK-1 [122]. A
direct interaction between Crk and JNK may indeed be
biologically relevant, since studies by Girardin and Yaniv
have shown that a JNK mutant (K340A) that fails to bind
Crk is also defective in EGFR signaling and Rac1 activation
[155]. These studies also suggest significant crosstalk
between JNK and Rac1, and the involvement of
DOCK180 in this pathway should be investigated. These
results may offer an explanation for the observations that
integrins regulate progression through the G1 phase of the
cell cycle in a JNK-dependent manner [156]. Following
integrin engagement, JNK activation requires association
of FAK with a Src kinase and p130Cas, the phosphoryla-
tion of p130Cas, and subsequently, the recruitment of
Crk. FAK-JNK signaling appears to be necessary for proper
progression through the G1 phase of the cell cycle. These
findings suggest a role for p130Cas and Crk in both the
activation of JNK and control of the cell cycle, as well as
identification of a physiological stimulus for JNK signal-
ing that is consistent with the role of Jun in both prolifer-
ation and transformation. There also appears to be
significant crosstalk between these pathways. Finally, in
Drosophila melanogaster, downstream of platelet-derived
growth factor receptor (PDGFR) or vascular-endothelial
growth factor receptor (VEGFR), Crk/DOCK180/ELMO/
Rac interactions mediate JNK activation, leading to dorsal
closure [157].
Crk and Abl
Abl is a non-receptor tyrosine kinase first identified as the
cellular homolog of the v-Abl oncogene product of the
Abelson murine leukemia virus, and has multiple roles in
cell growth, transformation, cell stress, apoptosis, and
remodeling of the actin cytoskeleton. Arg (Abl-related
gene) is over 70% homologous to Abl, and both proteins
contain four tandem proline-rich motifs located just C-
terminal to the kinase domain [10,158] that mediate
binding to the N-terminal Crk SH3 domain. Systematic
mutagenesis studies whereby each of the four proline-rich
motifs was assigned function and SH3 domain specificity
showed that motifs 1, 2, and 4 (from the N-terminus to
the C-terminus) predominantly bound Crk, whereas
motif 3 was more promiscuous and bound SH3 domains
of Nck, Ponson/CAP, and ArgB2 [159]. Moreover, in
reconstitution studies in NIH3T3 cells, it was further
shown that binding of Crk and Nck promoted distinct
morphological phenotypes upon adhesion to ECM; Crk
stimulated lamellipodia formation (via Rac1) while Nck
stimulated filopodia formation (via Cdc42). This suggests
that binding of Crk to the Abl proline-rich motifs is bal-
anced to fine-tune actin-based membrane dynamics as
cells adapt to their surrounding environment. This is
likely functionally important for integrin function, as cell
adhesion and integrin ligation induces p130Cas tyrosine
phosphorylation and the translocation of Abl from the
nucleus to focal adhesions, where focal adhesion-associ-
ated Abl contributes to adhesion-dependent actin reor-
ganization and membrane ruffling [160,161]. One of the
critical functions of Abl in focal adhesions is to regulate
the formation and maintenance of adherens junctions via
a Crk and Rac1 pathway that regulates cadherin-catenin
adhesion complex [162]. Additionally, Abl has been
shown to tyrosine phosphorylate SOS1, which associates
with Abl most likely through Crk [163]. This might
explain why Rac1 is constitutively activated in Bcr-Abl
transformed cells, whereby Rac1 is implicated in increased
motility of the cancer cells.
In general, the interaction between Abl and Crk is sug-
gested to be bi-directional, meaning that Crk can both
transactivate Abl and Abl can transinhibit Crk II and CrkL.
Transactivation of Abl by Crk II was first reported byPage 11 of 23
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expresion of Crk and Abl increased the net tyrosine phos-
phorylation of cellular proteins in Abl-expressing cells
(Figure 4A). Subsequently, Reichman et al showed that
Crk expression with Abl induced tyrosine phosphoryla-
tion of the major autophosphorylation sites in Abl (Tyr
245 and Tyr 412), suggesting that Crk binding to Abl
directly enhances Abl enzymatic activity. Consistent with
this idea, Crk transactivation is much more efficient when
either the Y221 or the P225 motifs in Crk are substituted
to prevent Crk phosphorylation and intramolecular bind-
ing to its own SH2 domain [164,165]. Although structural
analysis is warranted to identify specific features of Abl
transactivation, biochemical studies indicated that trans-
activation is mediated by the SH3 linker in Crk as well as
the PNAY motif in the RT-loop of the C-terminal SH3
domain. It will also be important to decipher whether Crk
mediated transactivation induces phosphorylation on
specific substrates, as this would help elucidate functional
significance. Biochemical and cell biological studies also
suggest that Crk binding to Abl causes an increase in the
steady state levels of Abl [165], possibly to prevent degra-
dation. Abl is known to be degraded by either ubiquitin or
caspase-mediated pathways. In vitro, addition of the Crk
SH3N domain can reverse the inhibition of Abl activity by
F-actin, further suggesting that Crk transactivation may
occur locally in the focal adhesions [166].
Subsequent to the binding and transactivation of Abl by
Crk, Crk Y221 is itself an excellent substrate for Abl, and
binding of Crk to Abl reflects a potent downmodulatory
signal [108]. However, while phosphorylation of Tyr221
may be the ultimate fate for the Crk/Abl interaction, few
studies have attempted to understand in detail what hap-
pens between the initial binding of Crk to Abl and the
ensuing Abl-mediated Crk phosphorylation. This should
be an important avenue of future investigation with goals
to identify transition state conformers of Abl and Crk, as
well as, to attempt to generate various activation state
mutants of Crk or Abl that reflect these transition states.
For example, in rodent and human Crk, binding of Crk to
Abl causes conformational changes that expose a PPPP
motif in the Crk SH2 domain that in turn binds the SH3
domain of Abl to stabilize the Abl/Crk interaction
[167,168]. Moreover, virtually nothing is known about
how Crk binding to Abl influences the C-terminal region
of Abl, including the ability of Abl to bind F-actin or to
DNA. Clearly, one important function of Y221 phoshor-
ylation is to prevent unregulated transactivation of com-
plexes involving Crk and Abl. However, physiologically, it
is more likely that the dynamic state of activation and
deactivation of Abl by Crk represents another example of
dynamic regulation to fine-tune signals related to Rac1
activation, actomyosin plasticity, and motility.
Tyrosine phosphorylation of Crk on Y221 is also not of
inconsequence with respect to signal transduction path-
ways initiated by integrins and growth factors that led to
p130Cas phosphorylation. Klemke and colleagues were
the first to demonstrate that Abl inducible Crk Y221 phos-
phorylation acted as a molecular switch to dissociate a
p130Cas/Crk/DOCK180 ternary complex, in order to
block motility and invasive behavior of human pancreatic
cancer cells [54] (Figure 4B). More recently, a similar neg-
ative regulatory network has been reported for a p130Cas/
Crk/C3G ternary complex, whereby Abl promotes Crk
Y221 phosphorylation and disrupts the interaction
between Crk and C3G. This subsequently leads to
decreased activation of Rap1-GTP, decreased affinity of β1
integrin to ECM, and loss of cell adhesion [169]. Abl also
appears to have a negative regulatory role in HGF-stimu-
lated hepatocytes, where Crk Y221 phosphorylation
inhibits complex formation between Crk and Cbl [170].
Interestingly, in tumor cells tyrosine phosphorylation of
Crk by Abl may underscore a novel anti-oncogenic path-
way. For example, Noren et al have shown that EphB2
receptor tyrosine kinase acts as a tumor suppressor in
breast cancer cells and that depletion of EphB2 or its lig-
and ephrinB2 prediposes breast cancer cells to invasion
and metastasis [31]. These investigators further found that
ephrinB2 induces Crk Y221 phosphorylation and
decreased Rac1 activation. While this indicates that under
some conditions Abl-mediated Crk phosphorylation may
inhibit oncogenicity, it does raise a paradox as to whether
Imatinib (Gleevec), may have side effects when used to
treat CML.
Finally, a very interesting study by Peterson and Long
identified an important functional role in inhibitory sign-
aling downstream of the human killer cell Ig-like receptor
(KIR) that inhibits Natural Killer (NK) cell activation and
The multiple fates of Crk and Abl interactionsFigure 4
The multiple fates of Crk and Abl interactions. Crk 
binding to the proline-rich region of Abl induces Abl transac-
tivation (indicated by circle enclosing The (P). Subsequent to 
Abl activation following Crk binding, Abl phosphorylates Crk 
on Tyr-221, causing dissociation of the Abl and Crk complex. 
The fate of activated Abl is not known, but some studies indi-
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whereby NK cells either activate or inhibit target cell kill-
ing through a HLA class I receptor, these investigators
determined that the killing phenotype correlated with the
assemblage of a Cbl/Crk/C3G complex, whereas the
inhibitory phenotype correlated with the formation of a
complex with Abl and Crk, and the phosphorylation of
Crk to disassemble the aforementioned complex with
C3G [171]. This study defines an unusual role for Abl and
Crk assemblages in the signaling of inhibitory receptors.
Recent studies also suggest that pY221Crk is not necessar-
ily a biologically inert species. Interesting work by Vuori
and colleagues showed that pY221 Crk was required for
recruiting activated Rac1 to the membrane fraction, and
Rac1 re-localization was prevented by expression of the
Y221F Crk mutant [172]. Most interestingly, targeting of
CrkY221F to the plasma membrane by fusing a CAAX box
rescued the ability of Crk to localize Rac1 and promote
laemellipodial formation and migration. Further support
of a dynamic, rather than a static, role of Crk Y221 phos-
phorylation came from studies showing that Y221F Crk II
expression prevents regulated turnover of Crk/Abl/
p130Cas or Crk/Abl/paxillin complexes, leading to
impaired adhesion and migration [173]. Taken together,
these data suggest that regulated phosphorylation of
CrkY221 by Abl and Arg are not a simple on-and-off
mechanism, but rather a dynamic process to execute Crk-
dependent signaling involving Rac1 activation and cell
migration.
Regulatory role of the C-terminal region of Crk II and 
domain-domain communication
Since the discovery of v-Crk and c-Crk II, it is clear that the
C-terminal region exerts negative regulation on Crk sign-
aling and transformation. Whereas models for protein
interactions mediated by the SH2 and SH3N have been
well documented to explain how Crk functions as an
adaptor protein [14,168,174], how the C-terminus of Crk
imposes negative regulation has only recently begun to be
unraveled [15,175-178]. Earlier biochemical studies sug-
gested that the Crk SH3C could impose regulation on the
adaptor protein function of Crk. For example, when
expressed in Rat 3Y1 cells, the SH3C domain suppressed
p130Cas phosphorylation and the transforming potential
of Crk II, and negatively regulated EGF signaling to Ras
[179]. Mutations in the SH3C of Crk also lead to increased
association of Abl with the SH3N, suggesting that the
SH3N and SH3C functionally interact [180]. This latter
study also revealed that disruption of the boundary
between the SH3 linker and the SH3C domain (aa 240–
296 in chicken Crk) regulated the activation of FAK and
increased the numbers of focal adhesions in cells. This
paradigm for autoinhibition of the SH3 linker and SH3C
domain suggested that regions independent of the Y221
might contribute to the negative regulation of Crk.
NMR studies on various Crk proteins that contain the
SH3C domain and SH3 linker have begun to offer expla-
nations as to the nature of its regulatory aspects. Like the
Y221YAQP motif, the SH3C contributes to the negative
regulation of Crk II and CrkL by intramolecular domain
crosstalk. Although the Crk SH3C is highly conserved
from C. elegans to mammals, there are notable differences
in the Crk SH3C compared to canonical SH3 domains
that bind PxxP motifs. First, although the amino acids that
comprise the structural elements of the hydrophobic core
are highly conserved, the amino acids that comprise the
surface of the SH3C, in particular, where the PxxPxK is
expected to bind, are highly divergent [165,176]. The
charged residues on the surface of the SH3 domain that
interact with the P1, P3, and K6 residues are replaced by
unusually polar and bulky amino acids, precluding a
socket structure for the prolines and providing a clear
explanation for why CrkSH3C does not bind PxxPx(K, R)
ligands. Indeed, inspection of the solution NMR structure
of the isolated murine SH3C does not show an obvious
binding grove, suggesting that this domain may not bind
to, or bind with low affinity, to target proteins [176].
Indeed, the only known protein that has been shown to
interact with the Crk SH3C domain is the nuclear export
protein Crm1, which is posited to bind to a
LALEVGELVKV sequence in the Crk SH3C, and has broad
similarity to a nuclear export sequence (NES) [181]. How-
ever, in the monomer Crk proteins, the LVK motif is bur-
ied in the hydrophobic core of the SH3C and not likely to
form a contact surface. Interestingly, in the case of the
CrkL SH3C, partial SH3 unfolding that may occur during
monomer to dimer transition in the nucleus, specifically
may expose this LVK sequence for Crm1 binding [175].
This suggests that, in the context of nuclear Crk, regulated
unfolding of the SH3C domain may provide a novel and
unexpected regulatory mechanism for Crk efflux. Future
studies aimed at identification of the molecular mecha-
nisms of Crk unfolding, and whether this reflects an anti-
apoptotic mechanism warrant further investigation [182].
To better understand the mechanism by which the SH3C
and linker regulate the SH3N, Kalodimos and coworkers
used NMR analysis on a SH3N-linker-SH3C fragment of
chicken Crk [178] (Figure 5). In solution at pH 5.5, this
fragment showed characteristics of two species in slow
exchange originating from cis-trans isomerization at the
proline from the PFY motif at the boundary of the linker-
SH3C, a region previously identified as an important neg-
ative regulatory region in chicken Crk [180]. Moreover,
the cis and trans forms appear to have entirely different
regulatory functions: the cis isomer is locked in a configu-Page 13 of 23
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while the trans configuration appears extended and flexi-
ble (Figure 5). Support of this model comes from the fact
that mutation at either Pro238 or F239 abrogates cis-trans
isomerization, favoring the trans form and leading to
increased association of Abl with the SH3N [178]. By
sequence analysis, this proline was expected to be a sub-
strate for Cyclophilin A (CypA), a protein that has pepti-
dyl prolyl isomerase activity and catalyzes the prolyl
isomerization of peptide bonds. Interestingly, this sug-
gests that enzymatic-catalyzed cis-trans proyl isomeriza-
tion may influence Abl and Arg dependent
phosphorylation and hence the rate at which Crk proteins
are negatively regulated. Future studies should investigate
the physiological significance of CypA on Crk function, as
well as whether cyclosporin A (inhibitor of CypA) may be
a specific inhibitor of Crk pathways in vivo. Another inter-
esting aspect of this regulatory mechanism involving the
PFY motif in chicken Crk is that F239, adjacent to P238,
was absolutely required to achieve cis-trans isomerization,
and mutation of F239 to Ile or Val abrogated this regula-
tory mechanism. This is most intriguing, given the fact
that chicken is the only species of Crk with the PFY motif.
This motif diverges to PIY in human and PVY in mouse
(Figure 6).
Recently, Inagaki and colleagues performed NMR of the
entire structure of Crk I and Crk II and the phosphorylated
form of Crk II without the SH3C (amino acids 1–228)
[15] (Figure 7A). Interestingly, while the SH2 and SH3
domains of Crk I are flexible [15], conversely, Crk II forms
a compact structure. Solution structure of Crk II showed
that the three SH domains were assembled to a central
short sequence, residing in the inter SH3 region (amino
acids 224–237) called the inter SH3 core region (ISC),
and that this compact structure was stabilized mainly by
the SH3C domain. These studies also found that the
SH3N is semi-closed and covered by the bottom of the
SH2 domain, mimicking the interaction of SH3 and Pxx-
SH3N and SH3C domain communication in chicken Crk II is mediated by interaction of CyPAFigure 5
SH3N and SH3C domain communication in chicken 
Crk II is mediated by interaction of CyPA. Prolyl cis-
trans isomerization centered on P238FY regulates intradomain 
communication between the SH3N and SH3C domains. In 
the cis configuration, the SH3C or Crk forms a closed struc-
ture over the SH3N, preventing its association with proline-
containing binding partners. In the trans configuration, the 
linker and SH3N are extended, releasing negative regulation. 
Blue = SH3N; Orange = SH3C; Green = CypA.
Sequence alignment of various Crk speciesFig re 6
Sequence alignment of various Crk species. Chicken 
Crk is unique in possessing a PFY motif. As alluded to in the 
text, this may imply that chicken Crk is uniquely regulated by 
prolyl cis-trans isomerization. Shown in the right side of the 
figure is a schematic representaion depicting accessibility in 
the different conformations.
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NMR analysis of the structure of Crk II and pCrkIIFigure 7
NMR analysis of the structure of Crk II and pCrkII. 
(A) NMR structure of CrkII (1–304) and phosphorylated 
form of CrkII (1–228). SH2, SH3N, and SH3C are indicated 
as red, green, and blue colors. Inter SH3 core region (224–
237) of CRKII is indicated as yellow. In pCrkII, interface of 
SH3N is covered with the sequence between SH2 and SH3N 
(122-133 as magenta). Phosphorylated residue of pYAQP is 
indicated as light blue. (B). Schematic structure of CrkII with 
SH3N target C3G. In the cytoplasm, equilibrium of CrkII 
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tion of previously observed differences in the biological
activity of Crk I versus Crk II, including the fact that the
affinity of Crk II for the SH3N target polyproline motifs is
lower than the affinity of Crk I. Upon phosphorylation,
the entire Crk structure is dramatically shifted, and the
SH2 binds to phospho-Y221, as reported previously. In
phosphorylated Crk II, the SH3N surface was shown to be
blocked by an internal sequence between the SH2 and
SH3 domains (Arg122- Glu133), suggesting that phos-
phorylated Crk II cannot bind to either of the SH2 or
SH3N targets (Figure 7A). Again, these observations are
consistent with previous biochemical and cell biological
studies, which predict that: (i) Crk I is constitutively
active, (ii) Crk II is regulated by the intramolecular SH3N
interaction, and (iii) phosphorylated Crk appears to be
completely shut off for binding effector proteins (Figure
7B and additional File 1). Moreover, although details
remain to be determined, it appears that the mode of neg-
ative regulation for mammalian and chicken Crk II pro-
teins has somewhat diverged.
Complex Cell Biological Processes regulated by Crk II
Role of Crk in Rac1 activation, cell migration, and phagocytosis
A significant advance towards a molecular understanding
of Crk biology was revealed following a screen for genes
involved in cell-death pathways in C. elegans using classi-
cal worm genetics [59]. Earlier studies in C. elegans ele-
gantly identified genes that mediated the manifestations
of apoptosis (Ced-3/Caspases and Ced-4/APAF-1) and in
the suppression of apoptosis (Ced-9/Bcl-2) [183,184].
Upon closer examination of the worm phenotypes, a third
class of mutations was found, based on their inability to
engulf apoptotic corpses, and as such gave a phenotype of
persistent corpses. Four of these gene products, represent-
ing the dominant pathway for clearance in the worm,
were identified as a module consisting of Ced-2, Ced-5,
Ced-10, and Ced-12, which have the mammalian coun-
terparts, Crk II, DOCK180, Rac1, and ELMO, respectively
[185]. In addition to the defects in cell clearance in the C.
elegans model, a second related, if not overlapping, phe-
notype was noted in the Ced-2/Crk deficient worms that
involved defects in the migration of cells into the distal tip
[59]. Defects in distal tip migration could be rescued by
Ced10 (Rac1) or Ced5 (DOCK180), suggesting that Crk
was positioned upstream of Rac1 in this pathway. Investi-
gations by Ishimaru and Hanafusa, studying Drosophila
metamorphosis, elegantly demonstrated that Drosophila
Crk (Dcrk) cooperates with DOCK180 (called myoblast
city or Mbc) and ELMO for border cell migration in oog-
enesis and hemocyte migration during embryogenesis,
and further mapped this pathway downstream of PVR, the
fly equivalent molecule of PDGF Receptor and VEGF-
Receptor [157]. In addition to these functions in physio-
logical cell migration, Crk also appears to utilize cell
migration and motile responses in pathophysiological
functions that include pathogen uptake and virulence, as
well as cancer metastasis.
Crk and bacterial infectious diseases
In recent years, a growing and unexpected body of evi-
dence suggests that Crk may contribute to bacterial patho-
genesis by influencing entry into cells or by serving as
targets of bacterial toxins that disrupt essential cellular
function through Crk-dependent mechanisms. A role for
Crk in bacterial uptake pathways was first noted by Wei-
dow and colleagues, who demonstrated that Yersinia pseu-
dotuberculosis infection into human epithelial cells
activated the p130Cas-Crk-DOCK180-Rac1 pathway via
binding of the bacterial invasin to the β1 integrin receptor
[63,186]. This pathway appears be somewhat analogous
to the phagocytic pathway for apoptotic cells, although
the phagocytic pathway involves β3 and β5 integrins.
More recent studies by Burton and colleagues found that
Crk is also implicated in Shigella flexneri infection into
NIH 3T3 cells using a curious pathway involving Abl-Arg-
mediated Crk Y221 phosphorylation, whereby Crk Y221F
mutation blocked S. Flexneri infection [64]. In very pro-
vocative studies involving Pseudomonas aeruginosa infec-
tion [187] and Helicobacter pylori infection [66], Crk
appears to acquire a gain-of-function activity by co-opting
activities with bacterial virulence factors. In the former
study, a novel role for Abl and Crk phosphorylation was
identified and found to be essential for Pseudomonas aeru-
ginosa internalization [188]. In the case of H. pylori, Crk
associates with tyrosine phosphorylated CagA, and the
CagA/Crk complex regulates Erk signaling and Rac1-
mediated cytoskeletal assemblages [66]. Although in H.
pylori-associated gastric cancer, CagA-SHP2 signaling is
known to play a central role, the functional significance of
the CagA/Crk complex for cellular infection should be
evaluated. Finally, exoenzyme T (ExoT) of P. aeruginosa
ADP-ribosylates Crk I and Crk II at specific residues in the
SH2 domain (Arg20) that impairs binding of Crk to
p130Cas [187]. Although to date, there has been very little
to report on the role that Crk proteins play in viral entry
and pathogenesis, this may be an area of active ferment as
a recent study showed that CrkL can bind to NS1 proteins
in Influenza A infected cells [189].
Crk and human cancers
A number of studies have suggested that Crk may play an
important role in human cancers. Immunohistochemical
analysis of human cancers showed the over-expression of
Crk in adenocarcinomas of lung, breast, and stomach, and
also sarcomas, followed by the demonstration of
increased levels of Crk mRNA in more aggressive pheno-
types of lung adenocarcinoma [62,190-194]. In an analy-
sis of gene-expression profiles of 86 primary lung
adenocarcinomas, increased Crk expression was shown toPage 15 of 23
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shorter survival [190]. Overexpression of Crk in tumor
cells or in experimental model systems leads to increases
in tyrosine phosphorylation of p130Cas and the activa-
tion of an intracellular loop that further enhances the
activity of Crk and induces increased motility and the
aggressive potential of cancer cells. Therefore, Crk pro-
teins are not simply conduits for intracellular signal trans-
duction but also can control the amplitude of signaling.
Based on these observations, several groups have begun to
investigate the effects of Crk knockdown on the pheno-
typic behavior of human tumor cells. Simultaneous
downregulation of both Crk I and Crk II by siRNA dem-
onstrated the essential role of Crk in the malignant fea-
tures of human ovarian cancer cells [192], synovial
sarcoma cells [112], and brain tumors, such as glioblast-
oma cells [58]. Recent studies also suggest that Crk II is a
likely target for MiR-126, and that overexpression of MiR-
126 in lung cancer cells decreased adhesion, spreading,
and invasion [195]. In Crk knockdown cells, formation of
focal adhesion was decreased, and cells had cytoskeletal
disorganization, whereby formation of laemellipodial
structures at the leading edges of cells was impaired (Fig-
ure 8, additional file 2 and additional file 3). For example,
knockdown of Crk in human synovial sarcoma cells
showed a suppression of HGF-dependent activation of
Rac1 and decreased motility [192]. In glioblastoma cells,
Crk knockdown affected the early attachment to laminin.
In addition, Crk also regulated Rho-dependent phospho-
rylation of ezrin-radixin-moesin proteins that direct
migration towards hyaluronic acid in the brain [58].
Increased levels of Crk I mRNA are frequently observed in
WHO grade III and IV malignant gliomas [191,193].
Thus, Crk I expression may correlate with poor prognosis,
and this is a novel example of splicing-dependent control
of human cancer malignancy. As Crk knockdown in cell
lines was not lethal, Crk may be an effective therapeutic
target for decreasing the metastatic potential of human
tumor cells (see additional file 2 and additional file 3).
The above studies suggest that Crk may have a central role
in cell motility and metastasis in highly aggressive motile
cancer cells. There are a plethora of studies showing that
p130Cas-HEF and the FAK-Src circuitry is involved in
tumorigenesis, and Crk may indeed be an attractive target
due to its central integrative downstream role in signaling
by these molecules. Recent studies now suggest that
DOCK180 and/or ELMO may be oncogenes, or have
oncogenic potential, and Crk may be an attractive drug
target in tumor cells that use Rac1 activation to acquire
motile or metastatic potential. DOCK180, for example, is
overexpressed at the borders, but not at the centers, of
human malignant glioma, and together with ELMO1, it
regulates Rac activity to enhance tumor invasion [196].
Although the relation of C3G and human cancer is con-
troversial, an increase in C3G expression is observed in
human small cell carcinoma [197], and a Crk-C3G-Rap1
pathway leading to B-RAF and Erk activation is involved
in transformation downstream of Ret in papillary thyroid
carcinoma [124]. In addition, C3G activation of Rap1 reg-
ulates a number of cell-matrix or cell-cell interactions
through integrins and cadherins [130], pointing to a role
for C3G overexpression in the modulation of adherens
junctions, leading to tumor cell dissemination [130,198].
It will be important to experimentally observe whether
siRNA toward Crk can influence the motile behavior of
cells that express upregulated C3G and/or Rap-1. Finally,
a most curious function for CrkL has been recently pro-
posed, whereby a secreted form of CrkL was shown to
bind to the plexin-semaphorin-integrin (PSI) domain of
β1 integrin at the extracellular domain in order to pro-
mote cell growth and survival [213]. These authors made
the provocative suggestion that targeting extracellular Crk
proteins may have therapeutic value.
Effect of Crk siRNA on morphology and biological activity of human ova ian cancer cell line MCASFigure 8
Effect of Crk siRNA on morphology and biological 
activity of human ovarian cancer cell line MCAS. (A). 
Membrane ruffling is observed in the control MCAS cells (left 
panel), and siRNA for Crk suppressed these phenotypes 
(middle). When Crk is overexpressed, clear ruffling appeared 
(right, yellow color indicates Crk expression). (B). Control 
MCAS cells form metastatic nodules in the peritoneal cavity 
mimicking peritonitis carcinomatosa of human ovarian cancer 
patients when cells are injected into the peritoneal cavity of 
nude mice. H&E stain for lymphatic invasion of the peritoneal 
wall is displayed (left). Crk depleted cells by siRNA lose their 
malignant potential (right). [See additional file 2] (i) Human 
synovial sarcoma cell line Fuji with control siRNA was stimu-
lated with HGF. (ii) Human synovial sarcoma cell line Fuji 
with CRK siRNA was stimulated with HGF. Note that the 
cells exhibit flat morphology and their movement is static.
A
Control Crk-siRNA Crk-siRNA +
Crk re-expression
B
Control Crk-siRNAPage 16 of 23
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phosphorylation of CrkL and Crk II in CML [199-201].
This cancer results from the chromosomal translocation
termed Philadelphia chromosome (Ph1) as t(9;22), gen-
erating the aberrant chimeric protein Bcr-Abl. Current
understanding is that CrkL is not essential for the develop-
ment of CML, because CrkL knockout mice developed
CML by the introduction of Bcr-Abl. However, the full role
of CrkL and Crk II in CML has yet to be explained.
Crk and pro-apoptotic pathways
In recent years, both Crk II and CrkL have been implicated
in nuclear signal transduction events. For CrkL, elegant
studies have shown that CrkL binds tyrosine phosphor-
ylated Stat5 in Bcr-Abl expressing cells, and in a variety of
cytokine-stimulated hematopoietic cells [202,203]. In
many, if not all, of these cases, the complex translocates to
the nucleus to bind STAT5-responsive elements
[204,205]. Although Crk II can also bind to STAT5, this
complex does not appear to enter the nucleus, nor do anti-
Crk II antisera supershift STAT5 DNA binding complexes
[34]. While these studies may indicate that CrkL has a role
in transcription of interferon regulated genes, interesting
studies by Kornbluth and colleagues indicate that Crk
may actively and directly participate in apoptosis in Xeno-
pus by activating caspases [181]. Depletion of Crk II from
egg extracts prevented apoptosis, and these studies further
demonstrated that Crk binds to the cell cycle regulatory
protein Wee1, implying that this pro-apoptotic function
of Crk II may be due to nuclear localization [206]. Evi-
dence in support of this model includes the fact that Crk
has a putative NES in the SH3C domain, that when
mutated increases cell death, and that ionizing radiation
increases complex formation between Wee1 and Crk II.
Furthermore, evidence for a direct role of Crk in apoptosis
is supported by the findings that specific targeting of Crk
to the nucleus by fusing NLS sequences, spontaneously
activates apoptosis and potentiates stimuli that induce
apoptosis [182]. Recent structural studies with CrkL indi-
cate that the Crk NES may only function in the dimeric
state of the protein, mediated by a homotypic interaction
in the SH3C domains [175]. These studies predict that the
Crk NES motif may become exposed conditionally under
certain circumstances, an event that would actively pro-
mote efflux of a nuclear Crk pool into the cytoplasm.
However, the presence of an NES sequence in Crk II does
not explain how Crk II initially trafficks to the nucleus,
since Crk does not appear to possess any NLS sequences.
It will be equally important to characterize the physiolog-
ical signals that result in Crk translocation into the
nucleus, and whether there exists a regulatory signal that
controls the interaction between Crk and Crm1.
Future directions and new frontiers
The Crk gene was identified about 20 years ago, and the
characterization of Crk and its mode of cell signaling has
arguably revolutionized the way we think about intracel-
lular signal transduction. Despite significant advances and
an enormous wealth of new information, the field is now
faced with the challenging problem of how these complex
signaling networks are controlled in time and space to
produce biological responses. Efforts will need to be redi-
rected from the relatively simple task of identifying spe-
cific effector proteins to an understanding of when and
where these complexes are formed in cells. Development
of FRET technology that reports specific protein-protein
interactions, as well as the generation of a battery of phos-
phospecific antiseras against specific post-translational
epitopes, should help provide a better understanding of
Crk biology. This exciting field can expect substantial
progress as the new observations continue. One thing is
certain: the field of Crk biology will continue to grow over
the next 20 years.
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